Radiological findings in 75 cases of aneurysmal bone cyst were analyzed. Sixty-five per cent were primary or simple and 35% were secondary, the aneurysmal bone cyst being combined with other osseous lesions. A primary aneurysmal bone cyst can be diagnosed with a high degree of certainty, but only 20% of secondary forms had the radiological appearance of aneurysmal bone cyst; in the other 80% the associated lesion dominated the radiological picture, particularly when it was malignant. In the secondary form a small biopsy specimen may show the features of aneurysmal bone cyst only; without radiological assistance a concomitant malignant lesion may be missed. Therefore, there must be close collaboration between the radiologist and and the pathologist.

Fifty-seven aneurysmal bone cysts which were associated with or secondary to other lesions of bone are reported. The most common associations were with solitary or unicameral bone cyst, and with osteoclastoma. Other associated lesions included osteosarcoma, nonosteogenic fibroma, osteoblastoma, hemangioendothelioma, and hemangioma of bone. Five aneurysmal bone cysts were secondary to fracture or other bone trauma.

No abstract

Two hundred seventy‐five patients with breast cancer and no axillary metastases had mastectomies and axillary node dissection performed during the period between 1970 and 1979 at The Fox Chase Cancer Center. They had a mean age of 60 years (range, 21–91) and 38 (14%) patients have had recurrence to date. Poor histologic differentiation and skin involvement were related to a high risk of recurrence. Those patients with skin infiltration by tumor or a poorly differentiated tumor had a 53 ± 9% expected five‐year tumor‐free survival, whereas patients without these had a 90 ± 2% expected five‐year tumor‐free survival. Tumor involvement of the lymphatic vessels within the breast and estrogen receptor protein positivity or negativity were not helpful for identifying a subpopulation at increased risk of recurrence. Large tumor size was not a poor prognostic indicator for a patient subpopulation. These factors should be considered as indicators for inclusion in clinical trials and adjuvant therapy and used as stratification points for the analysis of the data developed in these trials. Cancer 50:1820‐1827, 1982.